Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy

doi:10.1159/000505693

Chia Nan University of Pharmacy & Science Institutional Repository > 智慧生活學院 > 醫務管理系(所) > 期刊論文 > Item 310902800/34130

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34130

標題:	Development and Validation of a Nomogram for Patients with Nonmetastatic BCLC Stage C Hepatocellular Carcinoma after Stereotactic Body Radiotherapy
作者:	Huang, Wen-Yen Tsai, Chiao-Ling Que, Jenny Y. Lo, Cheng-Hsiang Lin, Yu-Ju Dai, Yang-Hong Yang, Jen-Fu Shen, Po-Chien Lee, Mei-Hsuan Cheng, Jason Chia-Hsien
貢獻者:	Natl Def Med Ctr, Triserv Gen Hosp, Dept Radiat Oncol Natl Yang Ming Univ, Inst Clin Med Natl Taiwan Univ Hosp, Dept Oncol, Div Radiat Oncol Natl Taiwan Univ, Grad Inst Clin Med, Coll Med Chi Mei Med Ctr, Dept Radiat Oncol Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm Natl Taiwan Univ, Grad Inst Oncol, Coll Med
關鍵字:	Stereotactic body radiotherapy Nomogram Hepatocellular carcinoma
日期:	2020
上傳時間:	2022-11-18 11:25:15 (UTC+8)
出版者:	Karger
摘要:	Background:Stereotactic body radiotherapy (SBRT) is an emerging treatment modality for hepatocellular carcinoma (HCC) with promising outcome. However, appropriate survival prediction models are scarce. This study aimed to develop a simple and clinically useful prognostic nomogram for patients with nondistant metastatic Barcelona Clinic Liver Cancer (BCLC) stage C HCC undergoing SBRT.Methods:The data were based on a prospective multi-institutional registry enrolling 246 patients with nondistant metastatic BCLC stage C HCC treated with SBRT between January 1, 2008 and December 31, 2016. They were randomly divided into two subsets: 164 into the development cohort and 82 into the validation cohort. We identified and included prognostic factors for survival to derive a nomogram in the development cohort. The predictability of the nomogram was evaluated in the validation cohort. The area under the receiver operating characteristic curve (AUROC) and the calibration plot were used to evaluate the performance of the nomogram.Results:The median survival was 13.5 months, with 1- and 2-year overall survival (OS) rates of 55.0 and 32.9%, respectively. Number of tumors, largest tumor size, macrovascular invasion, Child-Turcotte-Pugh class, and biologically effective dose were significantly associated with OS (p< 0.05). These predictors were included to develop a nomogram with an AUROC of 0.77 (0.73-0.87). The prediction model was well calibrated in the validation cohort. The OS for patients who were divided by their risk scores differed significantly (p< 0.001).Conclusions:The nomogram we generated had discriminatory and satisfactory predictability for OS among nonmetastatic BCLC stage C HCC patients treated with SBRT. It demands further validations with cross-country data to confirm its worldwide usefulness.
關聯:	Liver Cancer, v.9, n.3, pp.12
顯示於類別:	[醫務管理系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
10.1159_000505693.pdf		581Kb	Adobe PDF	167	檢視/開啟
index.html		0Kb	HTML	455	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....